Literature DB >> 24361238

p38α regulates SERCA2a function.

Leena Kaikkonen1, Johanna Magga1, Veli-Pekka Ronkainen2, Elina Koivisto1, Ábel Perjes1, J Kurt Chuprun3, Leif Erik Vinge4, Teemu Kilpiö1, Jani Aro1, Johanna Ulvila1, Tarja Alakoski1, James A Bibb5, Istvan Szokodi6, Walter J Koch3, Heikki Ruskoaho7, Risto Kerkelä8.   

Abstract

cAMP-dependent protein kinase (PKA) regulates the L-type calcium channel, the ryanodine receptor, and phospholamban (PLB) thereby increasing inotropy. Cardiac contractility is also regulated by p38 MAPK, which is a negative regulator of cardiac contractile function. The aim of this study was to identify the mechanism mediating the positive inotropic effect of p38 inhibition. Isolated adult and neonatal cardiomyocytes and perfused rat hearts were utilized to investigate the molecular mechanisms regulated by p38. PLB phosphorylation was enhanced in cardiomyocytes by chemical p38 inhibition, by overexpression of dominant negative p38α and by p38α RNAi, but not with dominant negative p38β. Treatment of cardiomyocytes with dominant negative p38α significantly decreased Ca(2+)-transient decay time indicating enhanced sarco/endoplasmic reticulum Ca(2+)-ATPase function and increased cardiomyocyte contractility. Analysis of signaling mechanisms involved showed that inhibition of p38 decreased the activity of protein phosphatase 2A, which renders protein phosphatase inhibitor-1 phosphorylated and thereby inhibits PP1. In conclusion, inhibition of p38α enhances PLB phosphorylation and diastolic Ca(2+) uptake. Our findings provide evidence for novel mechanism regulating cardiac contractility upon p38 inhibition.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AMVM; ARVM; Cardiac contractility; ET-1; G protein coupled receptor kinase; GRK; I-1; MAPK; NRVM; OA; PLB; PP1; PP2A; Phospholamban; SERCA2a; adult mouse ventricular myocyte; adult rat ventricular myocyte; dn; dominant negative; endothelin-1; inhibitor-1; mitogen-activated protein kinase; neonatal rat ventricular myocyte; okadaic acid; p38; phospholamban; protein phosphatase-1; protein phosphatase-2A; sarco/endoplasmic reticulum Ca(2+) ATPase

Mesh:

Substances:

Year:  2013        PMID: 24361238      PMCID: PMC4296568          DOI: 10.1016/j.yjmcc.2013.12.005

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  34 in total

Review 1.  Cardiac excitation-contraction coupling.

Authors:  Donald M Bers
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

2.  Type 1 phosphatase, a negative regulator of cardiac function.

Authors:  Andrew N Carr; Albrecht G Schmidt; Yoichi Suzuki; Federica del Monte; Yoji Sato; Carita Lanner; Kristine Breeden; Shao-Ling Jing; Patrick B Allen; Paul Greengard; Atsuko Yatani; Brian D Hoit; Ingrid L Grupp; Roger J Hajjar; Anna A DePaoli-Roach; Evangelia G Kranias
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

3.  Phosphorylation of protein phosphatase inhibitor-1 by Cdk5.

Authors:  J A Bibb; A Nishi; J P O'Callaghan; J Ule; M Lan; G L Snyder; A Horiuchi; T Saito; S Hisanaga ; A J Czernik; A C Nairn; P Greengard
Journal:  J Biol Chem       Date:  2001-01-29       Impact factor: 5.157

4.  The MKK6-p38 MAPK pathway prolongs the cardiac contractile calcium transient, downregulates SERCA2, and activates NF-AT.

Authors:  Catherine Andrews; Peter D Ho; Wolfgang H Dillmann; Christopher C Glembotski; Patrick M McDonough
Journal:  Cardiovasc Res       Date:  2003-07-01       Impact factor: 10.787

5.  Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases.

Authors:  J A Pitcher; J J Tesmer; J L Freeman; W D Capel; W C Stone; R J Lefkowitz
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

6.  The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy.

Authors:  P Liao; D Georgakopoulos; A Kovacs; M Zheng; D Lerner; H Pu; J Saffitz; K Chien; R P Xiao; D A Kass; Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

7.  p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes.

Authors:  Pu Liao; Shi-Qiang Wang; Su Wang; Ming Zheng; Meizi Zheng; Sheng-Jun Zhang; Heping Cheng; Yibin Wang; Rui-Ping Xiao
Journal:  Circ Res       Date:  2002-02-08       Impact factor: 17.367

8.  Essential role of troponin I in the positive inotropic response to isoprenaline in mouse hearts contracting auxotonically.

Authors:  Joanne Layland; David J Grieve; Alison C Cave; Emma Sparks; R John Solaro; Ajay M Shah
Journal:  J Physiol       Date:  2004-02-13       Impact factor: 5.182

9.  PKC-alpha regulates cardiac contractility and propensity toward heart failure.

Authors:  Julian C Braz; Kimberly Gregory; Anand Pathak; Wen Zhao; Bogachan Sahin; Raisa Klevitsky; Thomas F Kimball; John N Lorenz; Angus C Nairn; Stephen B Liggett; Ilona Bodi; Su Wang; Arnold Schwartz; Edward G Lakatta; Anna A DePaoli-Roach; Jeffrey Robbins; Timothy E Hewett; James A Bibb; Margaret V Westfall; Evangelia G Kranias; Jeffery D Molkentin
Journal:  Nat Med       Date:  2004-02-15       Impact factor: 53.440

Review 10.  Calcium flux balance in the heart.

Authors:  David Eisner; Elizabeth Bode; Luigi Venetucci; Andrew Trafford
Journal:  J Mol Cell Cardiol       Date:  2012-12-05       Impact factor: 5.000

View more
  10 in total

1.  Mitochondrial ROS Drive Sudden Cardiac Death and Chronic Proteome Remodeling in Heart Failure.

Authors:  Swati Dey; Deeptankar DeMazumder; Agnieszka Sidor; D Brian Foster; Brian O'Rourke
Journal:  Circ Res       Date:  2018-06-13       Impact factor: 17.367

Review 2.  The case for inhibiting p38 mitogen-activated protein kinase in heart failure.

Authors:  Pelin Arabacilar; Michael Marber
Journal:  Front Pharmacol       Date:  2015-05-12       Impact factor: 5.810

3.  Dickkopf‑3 upregulation mediates the cardioprotective effects of curcumin on chronic heart failure.

Authors:  Quan Cao; Junxia Zhang; Ling Gao; Yijie Zhang; Mingyan Dai; Mingwei Bao
Journal:  Mol Med Rep       Date:  2018-03-20       Impact factor: 2.952

Review 4.  Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure.

Authors:  Levi W Evans; Bradley S Ferguson
Journal:  Nutrients       Date:  2018-08-18       Impact factor: 5.717

Review 5.  On inotropic effects of UTP in the human heart.

Authors:  J Neumann; B Hofmann; U Gergs
Journal:  Heliyon       Date:  2019-08-02

6.  Heat Shock Protein 70 Protects the Heart from Ischemia/Reperfusion Injury through Inhibition of p38 MAPK Signaling.

Authors:  Nan Song; Jiao Ma; Xiao-Wen Meng; Hong Liu; Hui Wang; Shao-Yong Song; Qing-Cai Chen; Hua-Yue Liu; Juan Zhang; Ke Peng; Fu-Hai Ji
Journal:  Oxid Med Cell Longev       Date:  2020-04-07       Impact factor: 6.543

7.  Apelin increases cardiac contractility via protein kinase Cε- and extracellular signal-regulated kinase-dependent mechanisms.

Authors:  Ábel Perjés; Réka Skoumal; Olli Tenhunen; Attila Kónyi; Mihály Simon; Iván G Horváth; Risto Kerkelä; Heikki Ruskoaho; István Szokodi
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

8.  Cardiomyocyte GTP Cyclohydrolase 1 Protects the Heart Against Diabetic Cardiomyopathy.

Authors:  Hsiang-En Wu; Shelley L Baumgardt; Juan Fang; Mark Paterson; Yanan Liu; Jianhai Du; Yang Shi; Shigang Qiao; Zeljko J Bosnjak; David C Warltier; Judy R Kersten; Zhi-Dong Ge
Journal:  Sci Rep       Date:  2016-06-13       Impact factor: 4.379

Review 9.  p38 MAPK Pathway in the Heart: New Insights in Health and Disease.

Authors:  Rafael Romero-Becerra; Ayelén M Santamans; Cintia Folgueira; Guadalupe Sabio
Journal:  Int J Mol Sci       Date:  2020-10-08       Impact factor: 5.923

10.  GSK3β Serine 389 Phosphorylation Modulates Cardiomyocyte Hypertrophy and Ischemic Injury.

Authors:  Laura Vainio; Saija Taponen; Sini M Kinnunen; Eveliina Halmetoja; Zoltan Szabo; Tarja Alakoski; Johanna Ulvila; Juhani Junttila; Päivi Lakkisto; Johanna Magga; Risto Kerkelä
Journal:  Int J Mol Sci       Date:  2021-12-18       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.